HUTCHMED China Ltd (LSE:HCM) — Market Cap & Net Worth
Market Cap & Net Worth: HUTCHMED China Ltd (HCM)
HUTCHMED China Ltd (LSE:HCM) has a market capitalization of $21.25 Million (GBX174.68 Billion) as of September 17, 2026. Listed on the LSE stock exchange, this UK-based company holds position #25001 globally and #240 in its home market, demonstrating a -2.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HUTCHMED China Ltd's stock price GBX201.00 by its total outstanding shares 869070839 (869.07 Million). Also see total assets of HUTCHMED China Ltd for a full breakdown of the balance sheet.
HUTCHMED China Ltd Market Cap History: 2015 to 2026
HUTCHMED China Ltd's market capitalization history from 2015 to 2026. Data shows change from $29.50 Million to $21.25 Million (-1.14% CAGR). Also see cash efficiency ratio of HUTCHMED China Ltd for how efficiently the company converts equity into cash flow.
Index Memberships
HUTCHMED China Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$897.84 Million | 2.37% | #5 of 722 |
Weight: HUTCHMED China Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HUTCHMED China Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HUTCHMED China Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HCM live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.04x
HUTCHMED China Ltd's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
HUTCHMED China Ltd's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $24.00 Million | $216.08 Million | $11.70 Million | 0.11x | 2.05x |
| 2017 | $59.21 Million | $241.20 Million | -$26.74 Million | 0.25x | N/A |
| 2018 | $37.01 Million | $214.11 Million | -$74.81 Million | 0.17x | N/A |
| 2019 | $40.18 Million | $204.89 Million | -$103.68 Million | 0.20x | N/A |
| 2020 | $48.64 Million | $227.98 Million | -$125.73 Million | 0.21x | N/A |
| 2021 | $56.04 Million | $356.13 Million | -$194.65 Million | 0.16x | N/A |
| 2022 | $27.92 Million | $426.41 Million | -$360.83 Million | 0.07x | N/A |
| 2023 | $29.92 Million | $838.00 Million | $100.78 Million | 0.04x | 0.30x |
| 2024 | $24.85 Million | $630.20 Million | $37.73 Million | 0.04x | 0.66x |
| 2025 | $21.99 Million | $548.65 Million | $457.02 Million | 0.04x | 0.05x |
Competitor Companies of HCM by Market Capitalization
Companies near HUTCHMED China Ltd in the global market cap rankings as of September 17, 2026. Review HUTCHMED China Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to HUTCHMED China Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
HUTCHMED China Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, HUTCHMED China Ltd's market cap moved from $29.50 Million to $ 21.25 Million, with a yearly change of -1.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX21.25 Million | -3.37% |
| 2025 | GBX21.99 Million | -11.49% |
| 2024 | GBX24.85 Million | -16.96% |
| 2023 | GBX29.92 Million | +7.20% |
| 2022 | GBX27.92 Million | -50.19% |
| 2021 | GBX56.04 Million | +15.22% |
| 2020 | GBX48.64 Million | +21.05% |
| 2019 | GBX40.18 Million | +8.57% |
| 2018 | GBX37.01 Million | -37.50% |
| 2017 | GBX59.21 Million | +146.70% |
| 2016 | GBX24.00 Million | -18.64% |
| 2015 | GBX29.50 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of HUTCHMED China Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.25 Million USD |
| MoneyControl | $21.25 Million USD |
| MarketWatch | $21.25 Million USD |
| marketcap.company | $21.25 Million USD |
| Reuters | $21.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more